Cardiology in North Carolina

Halotherapy Solutions is a US-based supplier and manufacturer of salt therapy (halotherapy) and infrared sauna equipment serving wellness centers, spas, rehabilitation clinics, and medical facilities across all 50 US states and 20+ countries. The company specializes in dry salt therapy equipment—halogenerators that disperse pharmaceutical-grade salt particles into controlled environments—combined with infrared and red light therapy modalities. Primary product lines include the HaloSauna (1-, 2-, 3-, and 4-person infrared sauna cabins with integrated halotherapy), HaloRed (salt therapy with red light therapy), HaloMini (personal home-use halogenerator), and standalone halogenerators (HaloFX, HaloGX, HaloStar) for salt room installation. The company markets halotherapy for respiratory health, skin conditions, post-COVID recovery, asthma management, and general wellness. Equipment is compact, plug-and-play, requires minimal maintenance, and supports commercial daily-use environments. Halotherapy Solutions maintains BBB A+ accreditation and provides comprehensive customer support including installation assistance, training, and technical service. The company is positioned as the largest dry salt therapy equipment supplier in the world and serves diverse customer bases including day spas, wellness centers, physical therapy clinics, luxury hotel spas (e.g., Four Seasons Toronto), and home wellness users. Products are designed for ease of assembly and operation, with USP-Grade salt consumption efficiency emphasized in marketing materials.

Laboratory Corporation of America Holdings (Labcorp) is a global leader in laboratory services headquartered in Burlington, North Carolina. Operating in approximately 100 countries with over 70,000 employees, Labcorp performs more than 700 million tests annually and generates $13.01 billion in revenue. The company provides comprehensive clinical diagnostics, drug development support, and specialized testing including oncology, rare diseases, and genomic sequencing. Labcorp's integrated platform connects diagnostics to biopharma development, supporting healthcare providers, researchers, and investigators. Key offerings include AI-powered diagnostic assistance tools, real-world data platforms for drug development, genetic testing services (including Invitae), nonclinical research, central laboratory services, and clinical trial support. The company serves patients, healthcare providers, health systems, managed care organizations, and biopharmaceutical companies. Over 75% of new drugs approved by the FDA have been supported by Labcorp's services.

Intelerad Medical Systems is a leading provider of cloud-based medical imaging software and enterprise workflow solutions established in 1999. The company specializes in scalable PACS (Picture Archiving and Communication Systems), diagnostic imaging viewing, AI-enhanced reporting, secure image sharing, and clinical workflow orchestration. Intelerad's platform manages over 50 billion medical images and supports more than 300,000 clinicians conducting 140+ million exams annually. Key product offerings include IntelePACS® for image archival and management, InteleViewer™ for zero-footprint diagnostic viewing, InteleShare for secure patient imaging exchange, InteleOrchestrator for AI-powered clinical worklist prioritization, and InteleGence AI tools for precision diagnostics assistance. The company serves nearly 2,500 healthcare organizations globally—including radiology groups, hospitals, cardiology practices, and outpatient imaging centers—with operations across six countries and over 900 employees.

Ycellbio Medical Co., Ltd. manufactures first-in-class rapid kit technology for blood separation and platelet isolation. The company specializes in FDA-registered Class I medical devices designed to prepare autologous Platelet Rich Plasma (PRP) and Platelet Rich Fibrin (PRF) from whole blood samples at the point of care. The proprietary Ycellbio™-Kit blood separation tube utilizes a unique functional design to amplify centrifugal force, enabling rapid and efficient platelet isolation in a single 5-minute spin cycle. The technology delivers industry-leading 7–9x platelet concentration at approximately half the cost of competing kits. Products include the PRP Kit, PRP Evolution Kit, Starter Pack Pro, Starter Pack Lite, Centrifuge Conversion Kit, bulk tube packs (25-, 50-, and 100-tube), anticoagulant supplies, and a swing centrifuge. Ycellbio's devices are used globally in over 40 countries and are preferred by aesthetic medicine professionals offering facial rejuvenation and hair restoration therapies. The company provides clinical support and maintains a provider locator network. Manufacturing and regulatory compliance details indicate FDA registration and Class I medical device designation.

RAUMEDIC AG is a Germany-based (Helmbrechts) manufacturer specializing in polymer-based medical devices and pharmaceutical components. The company develops and manufactures tubing systems, catheters, cannulas, syringes, and infusion sets for cardiosurgery, cell and gene therapy, drug delivery, enteral feeding, infusion therapy, neuromonitoring, ophthalmology, orthopedics, and traumatology applications. RAUMEDIC operates an in-house online shop for single-use bioprocess equipment and offers comprehensive services including material expertise, product design, prototyping, manufacturing, and regulatory support (product registration guidance). The company maintains competencies across material development, product concept design, precision prototyping, and multiple manufacturing technologies. RAUMEDIC serves hospitals, pharmaceutical manufacturers, and biotech firms globally, with demonstrated commitment to sustainability including development of low-carbon footprint medical consumables. The company is headquartered in Germany with operations indicated in multiple markets.

Ingersoll Rand Inc. is a multinational industrial company based in Davidson, North Carolina, specializing in flow creation and life science and industrial solutions. Formed in February 2020 through the spinoff of Ingersoll-Rand plc's industrial segment and merger with Gardner Denver, the company operates across two main segments: Industrial Technologies and Services, and Precision and Science Technologies. With a 160-year heritage, Ingersoll Rand provides compressed air and vacuum systems, fluid management solutions, material handling equipment, and power tools across over 40 global brands. The company serves diverse markets including pharma, life sciences, laboratories, aerospace, food and beverage, water treatment, environmental, electronics, and manufacturing. With 17,000+ employees and 65+ manufacturing sites worldwide, Ingersoll Rand focuses on energy efficiency, productivity, and sustainability in industrial and precision sectors.

Lucerno Dynamics develops, manufactures, and markets the Lara® System, a passive skin sensor platform designed to detect and quantify radiolabeled biomarkers during nuclear medicine procedures. The system identifies radiopharmaceutical extravasations in seconds, evaluates injection impact within minutes, and reduces error frequency over time. Lara provides real-time quality control and assurance for nuclear medicine administrations, supporting patient-specific dosimetry and therapy response monitoring in solid tumors. With over 28,000 monitored administrations, Lucerno addresses a significant clinical gap: approximately 4.5 million extravasations annually occur in U.S. nuclear medicine procedures, with 500,000+ classified as significant. The system requires minimal patient experience impact (20 seconds added) and technologist workflow disruption (1 minute), making it practical for high-volume clinical settings seeking to enhance safety and procedural confidence.

CivaTech Oncology Inc. is a North Carolina-based medical device manufacturer specializing in innovative low dose rate (LDR) brachytherapy systems for cancer treatment. The company designs and commercializes polymer-encapsulated radioactive source devices that deliver localized radiation therapy to solid tumors while minimizing procedure time, trauma, and patient morbidity. Primary product lines include CivaString®, a linear polymer-encapsulated LDR brachytherapy source for treating prostate and other localized solid tumors; CivaSheet®, the only FDA-cleared unidirectional, bioabsorbable planar brachytherapy source; and CivaDerm™, a temporary radiation therapy product for intraoperative or surface treatment of skin cancer and other lesions. All products feature proprietary polymer encapsulation technology that eliminates hot/cold dose distribution spots, prevents source migration, and avoids long-term metal toxicity concerns associated with traditional metallic seeds. CivaString® and CivaSheet® are approved by the FDA and Nuclear Regulatory Commission as sealed sources for treating cancers of any solid tumor type, including prostate, pancreatic, sarcoma, head and neck, gynecologic, colorectal, breast, and brain malignancies. The company holds two NRC licenses in North Carolina (Agreement State), permitting broad research and manufacture/distribution of radioactive materials. Manufacturing operations comply with FDA guidelines and ISO 13485 international standards for medical device production in a cleanroom environment. The company has received NIH/NCI support and has published clinical outcomes demonstrating efficacy and safety. CivaTech's brachytherapy devices integrate seamlessly into existing clinical workflows from imaging through treatment planning and post-implant dosimetry.

Gilero is a contract development and manufacturing organization (CDMO) specializing in the design, development, and manufacturing of medical devices and drug delivery systems. Founded in 2002 and headquartered in Durham, North Carolina, Gilero became part of the Sanner Group in September 2024, expanding its global capabilities. The company offers comprehensive end-to-end services across the entire product lifecycle, including design and engineering, concept development, prototyping, clinical and small-batch manufacturing, electromechanical systems integration, human factors and usability engineering, regulatory affairs support, and full-scale contract manufacturing. Gilero operates over 300,000 square feet of ISO-certified cleanroom manufacturing facilities (ISO Class 7 and 8) across North America, Europe, and Asia, enabling both small-batch and high-volume production. With more than 130 engineers and regulatory experts, Gilero supports device development from initial concept through commercialization, serving diverse therapeutic areas including closed-system drug transfer devices, surgical instruments, ocular implant delivery systems, and hemostasis devices. The company combines expertise in biomedical, mechanical, electrical, and software engineering to deliver scalable manufacturing solutions tailored to client specifications and regulatory requirements.